Search
Glypromate
go.drugbank.com/drugs/DB05633ExperimentalNeuren Pharmaceuticals was developing Glypromate (glycine-proline glutamate), a naturally occurring small-molecule neuroprotectant derived from IGF-1 which inhibits caspase III dependent apoptosis, for
CERE-120
go.drugbank.com/drugs/DB05637InvestigationalCERE-120 is an investigational drug consisting of an adeno-associated virus (AAV) that was engineered to carry the human gene for neurturin, a neurotrophic (growth) factor.
Synonyms: adeno-associated virus serotype 2 [AAV2]-neurturin [NTN]Asvasiran
go.drugbank.com/drugs/DB05638InvestigationalAsvasiran is an siRNA that targets the respiratory syncytial virus (RSV) N gene and inhibits viral replication. It has the potential to treat or prevent RSV infection.
DDP-225
go.drugbank.com/drugs/DB05642InvestigationalDDP225 is both a noradrenaline reuptake inhibitor and a serotonin type 3 receptor (5-HT3) antagonist. … The unique combination of noradrenaline reuptake inhibition and 5-HT3 antagonism in one orally delivered compound represents a novel approach to treating IBS-d and other functional GI diseases.
Categories: Heterocyclic Compounds, 1-RingIRX-2
go.drugbank.com/drugs/DB05643InvestigationalIRX-2 contains a human leukocyte-derived cytokine mixture. It is being investigated to promote or enhance an anti-cancer immune response.
Synonyms: Cytokine-based biologic agent IRX-2VT-111
go.drugbank.com/drugs/DB05646InvestigationalVT-111 is a 55 kDa secreted glycoprotein belonging to a superfamily of proteins called SERPINS, which share a general structure and mechanism for proteinase inhibition.
Synonyms: Serp-1, Serine proteinase-1D-JNKI-1
go.drugbank.com/drugs/DB05660InvestigationalA synthetic, cell permeable peptide that blocks the MAPK-JNK signal pathway; has potential therapeutic value for long-term protection of both the morphological integrity and physiological function of the
Synonyms: D-JNKI 1 peptideNP-50301
go.drugbank.com/drugs/DB05662ExperimentalNP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals. … It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S.
EP-2104R
go.drugbank.com/drugs/DB05675ExperimentalIt is being developed by EPIX Pharmaceuticals, Inc. … EP-2104R is an imaging pharmaceutical under development for the detection of blood clots. It is the first targeted high-resolution technique designed to visualize blood clots directly.